Vaccine Development and the Costs of Uncertainty
Turn any article into a podcast. Upgrade now to start listening.
TL;DR
- The FDA refused to evaluate Moderna's mRNA flu vaccine, despite a $1 billion investment and positive trial data.
- The refusal, issued via a 'Refuse-to-File' letter, caused shock and concern within the vaccine industry regarding regulatory risks.
- Industry experts warned that unpredictable regulations could shift investment away from vaccine development.
- The FDA reversed its decision approximately a week later, agreeing to review the vaccine.
- The incident is seen as an example of policy shifts under new leadership, potentially impacting trust in established regulatory processes.
- The article links this event to the Trump administration's broader skepticism towards vaccines and mRNA technology, mentioning Health and Human Services Secretary Robert F. Kennedy Jr.